Presentation, patterns and predictive value of baseline liver tests on outcomes in COVID-19 patients without chronic liver disease.
COVID-19
Liver enzymes
Outcomes
Predictors
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Nov 2021
14 Nov 2021
Historique:
received:
30
01
2021
revised:
12
07
2021
accepted:
24
10
2021
entrez:
8
12
2021
pubmed:
9
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) infection is known to cause abnormal hepatic enzymes. The long term consequences of such elevations are uncertain. To assessed the prevalence and prognostic value of initial liver enzymes in a large cohort of COVID-19 patients. We reviewed electronic medical records of 10614 COVID-19 patients without known chronic liver disease who were admitted to our health system from March 1, 2020, to April 30, 2020. We analyzed baseline demographics and liver chemistries. The primary outcome was in-hospital mortality, and the secondary outcome was a composite of in-hospital mortality or need for mechanical ventilation. Subjects with abnormal liver tests had increased risks of mortality and composite outcome when compared to patients with normal measurements on unadjusted analysis and after adjustment for demographic factors. In our diverse patient population, liver enzyme abnormalities are associated with increased mortality and the need for mechanical ventilation in subjects without chronic liver disease. Cholestasis patients are at the greatest risk for poor outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) infection is known to cause abnormal hepatic enzymes. The long term consequences of such elevations are uncertain.
AIM
OBJECTIVE
To assessed the prevalence and prognostic value of initial liver enzymes in a large cohort of COVID-19 patients.
METHODS
METHODS
We reviewed electronic medical records of 10614 COVID-19 patients without known chronic liver disease who were admitted to our health system from March 1, 2020, to April 30, 2020. We analyzed baseline demographics and liver chemistries. The primary outcome was in-hospital mortality, and the secondary outcome was a composite of in-hospital mortality or need for mechanical ventilation.
RESULTS
RESULTS
Subjects with abnormal liver tests had increased risks of mortality and composite outcome when compared to patients with normal measurements on unadjusted analysis and after adjustment for demographic factors.
CONCLUSION
CONCLUSIONS
In our diverse patient population, liver enzyme abnormalities are associated with increased mortality and the need for mechanical ventilation in subjects without chronic liver disease. Cholestasis patients are at the greatest risk for poor outcomes.
Identifiants
pubmed: 34876794
doi: 10.3748/wjg.v27.i42.7350
pmc: PMC8611205
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7350-7361Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no conflicts of interest related to the content of the manuscript.
Références
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
Hepatology. 2020 Oct;72(4):1169-1176
pubmed: 32725890
Liver Int. 2021 Jan;41(1):20-32
pubmed: 33190346
Eur J Gastroenterol Hepatol. 2020 Dec 22;Publish Ahead of Print:
pubmed: 33369962
Am J Gastroenterol. 2020 Jun;115(6):941-942
pubmed: 32301760
Korean J Gastroenterol. 2019 Mar 25;73(3):132-140
pubmed: 31013556
Liver Int. 2020 Oct;40(10):2394-2406
pubmed: 32526083
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Gastroenterology. 2020 Sep;159(3):1137-1140.e2
pubmed: 32389667
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
J Hepatol. 2020 Nov;73(5):1231-1240
pubmed: 32553666
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
J Chin Med Assoc. 2020 Jun;83(6):521-523
pubmed: 32243269
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Hepatology. 2021 Mar;73(3):890-900
pubmed: 32415860
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Gastroenterol. 2021 May 1;116(5):1077-1082
pubmed: 33464757